Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer.

Abstract

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. March 28, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00460 Journal of Clinical Oncology - published online before print June 15, 2023 PMID: 37319388 Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer Stéphanie Kermorgant, PhD1xStéphanie KermorgantSearch for articles by this author Show More 1Spatial Signalling Group, Barts Cancer Institute–a CR-UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London, United Kingdom https://doi.org/10.1200/JCO.23.00460 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by Rosetrees Trust (M314 and M346), Barts Charity (MGU0511, G-001868, G-002205), and the MRC (MR/R009732/1).AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTRationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).No potential conflicts of interest were reported. Companion Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer